BNP Paribas Asset Management
SYRE icon

BNP Paribas Asset Management’s Spyre Therapeutics SYRE Stock Holding History

BNP Paribas Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$79.6K Buy
897
+9
+1% +$657 ﹤0.01% 1614
2026
Q1 		$44.8K Buy
888
+232
+35% +$8.75K ﹤0.01% 1783
2025
Q4 		$21K Buy
656
+321
+96% +$8.39K ﹤0.01% 1948
2025
Q3 		$6K Sell
335
-42
-11% -$685 ﹤0.01% 1796
2025
Q2 		$6K Buy
+377
New +$5.58K ﹤0.01% 1961

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BNP Paribas Asset Management's SYRE Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Spyre Therapeutics (SYRE) stake by 1% in Q2 2026, buying an estimated $657 and bringing the position to 897 shares worth $79.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1614.

BNP Paribas Asset Management first reported a position in SYRE in Q2 2025 and has held it in 5 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • BNP Paribas Asset Management held 897 shares of Spyre Therapeutics worth $79.6K as of Q2 2026.
  • BNP Paribas Asset Management bought 9 Spyre Therapeutics shares in Q2 2026, an estimated $657.
  • Spyre Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1614 holding.
  • BNP Paribas Asset Management first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.